Teclistamab in multiple myeloma with one to three previous lines of therapy (Registro nro. 22751)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 02984nam a2200265 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | spa |
| 100 ## - Autor | |
| Autor | Touzeau, Cyrille |
| Rol del Autor | Autor |
| 9 (RLIN) | 53813 |
| 245 ## - Titulo | |
| Titulo | Teclistamab in multiple myeloma with one to three previous lines of therapy |
| 300 ## - Páginas | |
| Paginación | páginas: 440-453 |
| 520 ## - Resumen | |
| Resumen | Background: The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear.<br/>Methods: We randomly assigned patients with relapsed or refractory multiple myeloma who had previously received one, two, or three lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide, to receive teclistamab or the investigator’s choice of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd). Antimicrobial prophylaxis and immune globulin replacement were recommended. The primary end point was progression-free survival as assessed by an independent review committee.<br/>Results: A total of 296 patients were assigned to teclistamab and 297 to PVd or Kd. At the interim analysis (median follow-up, 17.3 months), teclistamab significantly improved progression-free survival as compared with PVd or Kd (estimated 18-month progression-free survival, 69.8% vs. 26.9%; hazard ratio for disease progression or death, 0.29; 95% confidence interval [CI], 0.23 to 0.38; P<0.001). The percentage of patients with a complete response or better was higher with teclistamab than with PVd or Kd (65.9% vs. 16.8%, P<0.001). Overall survival was improved with teclistamab as compared with PVd or Kd (estimated 18-month overall survival, 79.2% vs. 68.6%; hazard ratio for death, 0.60; 95% CI, 0.43 to 0.83; P=0.002). Adverse events of grade 3 or 4 occurred in 84.9% of teclistamab recipients and in 76.3% of PVd or Kd recipients, with grade 5 adverse events in 6.5% and 3.5%, respectively. Cytokine release syndrome, mostly of grade 1 or 2, occurred in 66.0% of teclistamab recipients, and immune effector cell–associated neurotoxicity syndrome occurred in 4.1%. Grade 3 or 4 infection occurred in 41.6% of teclistamab recipients and in 29.0% of PVd or Kd recipients. Conclusions: Among patients with multiple myeloma and one to three previous lines of therapy, teclistamab significantly improved progression-free and overall survival as compared with PVd or Kd. Infections of grade 3 or 4 were common. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LEUCEMIA |
| 9 (RLIN) | 33873 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LINFOMA |
| 9 (RLIN) | 39360 |
| 700 ## - Autor Personal | |
| Autor Personal | Mina, Roberto |
| 9 (RLIN) | 53814 |
| 700 ## - Autor Personal | |
| Autor Personal | Quach, Hang |
| 9 (RLIN) | 53815 |
| 700 ## - Autor Personal | |
| Autor Personal | Hungria, Vania |
| 9 (RLIN) | 53816 |
| 700 ## - Autor Personal | |
| Autor Personal | Bhutani, Divaya |
| 9 (RLIN) | 53817 |
| 700 ## - Autor Personal | |
| Autor Personal | Chen, Wenming |
| 9 (RLIN) | 53818 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22638 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM005 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | SQB |
No hay ítems disponibles.